Zacks: Brokerages Anticipate Ionis Pharmaceuticals Inc (IONS) to Announce $0.14 Earnings Per Share

Share on StockTwits

Analysts expect Ionis Pharmaceuticals Inc (NASDAQ:IONS) to post earnings per share of $0.09 for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Ionis Pharmaceuticals’ earnings. The highest EPS estimate is $0.23 and the lowest is ($0.13). Ionis Pharmaceuticals reported earnings of $0.02 per share during the same quarter last year, which indicates a positive year-over-year growth rate of 350%. The firm is scheduled to issue its next earnings report on Tuesday, February 26th.

According to Zacks, analysts expect that Ionis Pharmaceuticals will report full year earnings of ($0.13) per share for the current year, with EPS estimates ranging from ($0.19) to ($0.10). For the next year, analysts anticipate that the company will post earnings of $0.25 per share, with EPS estimates ranging from ($1.24) to $2.71. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that that provide coverage for Ionis Pharmaceuticals.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its earnings results on Tuesday, November 6th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.13) by $0.10. Ionis Pharmaceuticals had a negative return on equity of 1.58% and a negative net margin of 7.52%. The business had revenue of $145.40 million during the quarter, compared to analysts’ expectations of $146.77 million. During the same period in the prior year, the firm posted ($0.02) EPS. Ionis Pharmaceuticals’s quarterly revenue was up 22.9% compared to the same quarter last year.

A number of equities analysts have recently issued reports on IONS shares. Stifel Nicolaus dropped their target price on Ionis Pharmaceuticals from $47.00 to $45.00 and set a “hold” rating for the company in a report on Tuesday, August 28th. Morgan Stanley dropped their target price on Ionis Pharmaceuticals from $49.00 to $45.00 and set an “equal weight” rating for the company in a report on Tuesday, August 28th. ValuEngine cut Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 7th. Piper Jaffray Companies set a $50.00 target price on Ionis Pharmaceuticals and gave the stock a “hold” rating in a report on Monday, September 24th. Finally, Zacks Investment Research cut Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 9th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and two have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $53.50.

In related news, COO Brett P. Monia sold 34,000 shares of the firm’s stock in a transaction on Friday, November 23rd. The stock was sold at an average price of $55.00, for a total transaction of $1,870,000.00. Following the completion of the sale, the chief operating officer now directly owns 49,841 shares of the company’s stock, valued at approximately $2,741,255. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP C Frank Bennett sold 12,500 shares of the firm’s stock in a transaction on Thursday, November 1st. The shares were sold at an average price of $49.54, for a total value of $619,250.00. Following the sale, the senior vice president now directly owns 31,896 shares of the company’s stock, valued at $1,580,127.84. The disclosure for this sale can be found here. Company insiders own 2.13% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the stock. TRUE Private Wealth Advisors acquired a new stake in Ionis Pharmaceuticals during the 3rd quarter valued at $133,000. Parallel Advisors LLC increased its holdings in Ionis Pharmaceuticals by 195.5% during the 3rd quarter. Parallel Advisors LLC now owns 3,023 shares of the company’s stock valued at $156,000 after purchasing an additional 2,000 shares in the last quarter. Clarus Wealth Advisors increased its holdings in Ionis Pharmaceuticals by 200.0% during the 3rd quarter. Clarus Wealth Advisors now owns 3,600 shares of the company’s stock valued at $186,000 after purchasing an additional 2,400 shares in the last quarter. Cambridge Investment Research Advisors Inc. acquired a new stake in Ionis Pharmaceuticals during the 2nd quarter valued at $212,000. Finally, IFG Advisory LLC acquired a new stake in Ionis Pharmaceuticals during the 3rd quarter valued at $225,000. 85.13% of the stock is owned by hedge funds and other institutional investors.

Shares of IONS opened at $53.12 on Friday. Ionis Pharmaceuticals has a 1 year low of $39.07 and a 1 year high of $59.81. The company has a quick ratio of 7.96, a current ratio of 7.99 and a debt-to-equity ratio of 0.74. The company has a market capitalization of $7.71 billion, a PE ratio of 664.00 and a beta of 2.38.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.

Recommended Story: How Short Selling Works

Get a free copy of the Zacks research report on Ionis Pharmaceuticals (IONS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.